Stock Events

Stock Events

Evelo Biosciences 

$0.000100
17
+$0.00+0% Monday 20:00

Statistics

Day High
0.0005
Day Low
0.0005
52W High
0.0005
52W Low
0.0001
Volume
133
Avg. Volume
195
Mkt Cap
1,893.1
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

22NovExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q3 2024
-3.78
-2.58
-1.39
-0.19
Expected EPS
-0.43
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
0Revenue
-114.53MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EVLO. It's not an investment recommendation.
Verizon Communications
4
VZ
Apple
3
AAPL
Microsoft
3
MSFT
Realty Income
3
O

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap1.91B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics, competing in the biotech space with novel treatments similar to Evelo's approach.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals is involved in creating transformative medicines for serious diseases, directly competing with Evelo's mission in the biotech industry.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals specializes in developing medications for rare and severe conditions, aligning as a competitor in the biotech field against Evelo.
Biogen
BIIB
Mkt Cap31B
Biogen focuses on neurology and rare diseases, competing with Evelo Biosciences in the development of innovative biotechnological treatments.
AMGEN
AMGN
Mkt Cap224.63B
Amgen is a biotech firm that develops a wide range of therapeutic products, potentially competing with Evelo's product pipeline.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences is known for its work in antiviral drugs and other areas of high unmet medical need, positioning it as a competitor to Evelo.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics is at the forefront of gene editing, a technology that could compete with Evelo's microbiome-based therapies.
Novartis
NVS
Mkt Cap286.78B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments in areas where Evelo Biosciences may also be aiming to innovate.
Moderna
MRNA
Mkt Cap25.28B
Moderna is known for its mRNA technology platform, competing in the innovative treatment space, including potential overlaps with Evelo's focus areas.

About

Evelo Biosciences, Inc. is a biotechnology firm dedicated to identifying and advancing oral biologic therapies for various inflammatory conditions and oncological diseases. Its pipeline includes EDP1815, a whole-microbe compound designed to address inflammatory ailments, currently undergoing Phase 2 clinical trials for conditions such as psoriasis and atopic dermatitis, and also being evaluated for the hyperinflammatory reaction associated with COVID-19. Additional developments include EDP1867, an inactivated oral biologic in Phase 1b for inflammatory diseases; EDP2939, an investigational oral biologic based on extracellular vesicles targeting inflammatory diseases; and EDP1908, a drug candidate focused on cancer. Established in 2014, Evelo Biosciences, Inc. operates from its headquarters in Cambridge, Massachusetts.
Show more...
CEO
Craig R. Jalbert
Employees
66
Country
United States
ISIN
US2997342025

Listings

OTC Link
US
EVLO

0 Comments

Share your thoughts

FAQ

What is Evelo Biosciences stock price today?▼
The current price of EVLO is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Evelo Biosciences stock price performance more closely on the chart.
What is Evelo Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Evelo Biosciences stocks are traded under the ticker EVLO.
Is Evelo Biosciences stock price growing?▼
EVLO stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Evelo Biosciences has showed a -80% decrease.
What is Evelo Biosciences market cap?▼
Today Evelo Biosciences has the market capitalization of 1,893.1
What is Evelo Biosciences revenue for the last year?▼
Evelo Biosciences revenue for the last year amounts to 0 USD.
What is Evelo Biosciences net income for the last year?▼
EVLO net income for the last year is -114.53M USD.
How many employees does Evelo Biosciences have?▼
As of August 19, 2026, the company has 66 employees.
In which sector is Evelo Biosciences located?▼
Evelo Biosciences operates in the Health & Wellness sector.
When did Evelo Biosciences complete a stock split?▼
The last stock split for Evelo Biosciences was on June 30, 2023 with a ratio of 1:20.
Where is Evelo Biosciences headquartered?▼
Evelo Biosciences is headquartered in Cambridge, United States.